Moreover, there were statistically significant interactions between female sex, ET phenotype, hydroxyurea use, JAK2 positivity, high-risk disease, and the presence of other cardiovascular risk factors with overall thrombotic risk, suggesting that special consideration and clinical surveillance should be targeted at this specific MPN patient subpopulation having these high-risk features [1,4]. Here, JAK2 is linked to myeloproliferative neoplasm.